TLP
ACET icon

Tri Locum Partners’s Adicet Bio ACET Stock Holding History

Tri Locum Partners’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-11,491
Closed -$2.68M – 42
2022
Q2 		$2.68M Sell
11,491
-21,213
-65% -$4.66M 1.1% 26
2022
Q1 		$10.4M Sell
32,704
-3,759
-10% -$865K 4.08% 10
2021
Q4 		$10.2M Buy
+36,463
New +$6.26M 4.02% 10

Other funds holding ACET

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Tri Locum Partners's ACET Position: Q3 2022 in Review

Tri Locum Partners sold out of Adicet Bio (ACET) in Q3 2022, closing a stake of 11,491 shares — an estimated $2.68M sold.

Tri Locum Partners first reported a position in ACET in Q4 2021 and held it in 3 quarters. The position peaked at $10.4M in Q1 2022. 102 funds tracked by Wall St. Rank hold ACET as of Q3 2022.

  • Tri Locum Partners reported no remaining Adicet Bio position as of Q3 2022 after selling out during the quarter.
  • Tri Locum Partners sold 11,491 Adicet Bio shares in Q3 2022, an estimated $2.68M.
  • Tri Locum Partners first reported a position in Adicet Bio in Q4 2021 and held it in 3 quarters.
  • Tri Locum Partners's Adicet Bio position peaked at $10.4M in Q1 2022.
  • 102 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2022.

Based on Tri Locum Partners's 13F filing for Q3 2022, filed 14 Nov 2022.